8 results on '"Yingze Wang"'
Search Results
2. Bioreducible Zinc(II)-Dipicolylamine Functionalized Hyaluronic Acid Mediates Safe siRNA Delivery and Effective Glioblastoma RNAi Therapy
- Author
-
Zhipeng Yang, Haigang Wu, Jeng-Wei Lu, Xing-Jie Liang, Amanda L. Wright, Albert Lee, Xue Xia, Meng Zheng, Yingze Wang, Shizhu Chen, Yang Liu, Jinchao Zhang, Huijun Yin, and Weimin Ruan
- Subjects
Small interfering RNA ,010405 organic chemistry ,Chemistry ,Genetic enhancement ,Biochemistry (medical) ,Biomedical Engineering ,chemistry.chemical_element ,02 engineering and technology ,General Chemistry ,Zinc ,021001 nanoscience & nanotechnology ,medicine.disease ,01 natural sciences ,0104 chemical sciences ,Biomaterials ,chemistry.chemical_compound ,Dipicolylamine ,RNA interference ,Hyaluronic acid ,medicine ,Cancer research ,Delivery system ,0210 nano-technology ,Glioblastoma - Abstract
RNA interference (RNAi) is an emerging therapeutic modality for tumors. However, lack of a safe and efficient small interfering RNA (siRNA) delivery system limits its clinical application. Here, we report a bioreducible and less-cationic siRNA delivery carrier by conjugating Zn(II)-dipicolylamine complexes (Zn-DPA) onto hyaluronic acid (HA) via a redox-sensitive disulfide (-SS-) linker. Such polymer conjugates can formulate stable siRNA nanomedicines via coordination between zinc ions of DPA and the anionic phosphate of siRNA. After the conjugates are taken up by cells, intracellular reduction stimulus subsequently triggers the release of siRNAs and elucidates the desired RNAi effect. Our studies showed the formulated siRNA nanomedicines can be efficiently delivered into tumor cells/tissues and mediates less cytotoxicities both in vitro and in vivo. More importantly, when applied in a xenograft glioblastoma tumor model, this siRNA nanomedicine demonstrated significantly enhanced antitumor ability comparing to naked siRNA. This work demonstrates that such bioreducible Zn-DPA-functionalized HA conjugates without using cationic material as a siRNA carrier represents a promising direction for RNAi-based cancer therapy.
- Published
- 2022
3. Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells
- Author
-
Yu Fu, Yingze Wang, and Weiye Shi
- Subjects
Cancer Research ,biology ,cell migration ,Cell growth ,Chemistry ,Glucose uptake ,Glucose transporter ,Articles ,Cell cycle ,Cell biology ,cell proliferation ,Oncology ,Downregulation and upregulation ,Anaerobic glycolysis ,biology.protein ,glucose transporter 3 ,serine threonine tyrosine kinase 1/novel oncogene with kinase domain ,Glycolysis ,aerobic glycolysis ,GLUT3 - Abstract
Serine threonine tyrosine kinase 1 (STYK1)/novel oncogene with kinase domain (NOK) has been demonstrated to promote cell carcinogenesis and tumorigenesis, as well as to strengthen cellular aerobic glycolysis, which is considered to be a defining hallmark of cancer. As the carriers of glucose into cells, glucose transporters (GLUTs) are important participants in cellular glucose metabolism and even tumorigenesis. However, to the best of our knowledge, the role of GLUTs in biological events caused by STYK1/NOK has not yet been reported. The present study assessed GLUT3 as a key transporter, and glucose consumption and lactate production assays revealed that downregulation of GLUT3 impaired STYK1/NOK-induced augmented glucose uptake and lactate production, and RT-qPCR and western blotting confirmed that GLUT3 knockdown attenuated the STYK1/NOK-induced increase in the expression levels of key enzymes implicated in glycolysis. Furthermore, MTT and Transwell assays demonstrated that STYK1/NOK-triggered cell proliferation and migration were also markedly decreased following knockdown of GLUT3. To the best of our knowledge, the present study is the first to demonstrate that GLUT3 serves a prominent role in STYK1/NOK-driven aerobic glycolysis and cell proliferation characteristics. These findings may provide a clue for the investigation of the oncogenic activity of STYK1/NOK and for the identification of potential tumor therapy targets associated with GLUT3.
- Published
- 2021
4. Camptothecin-based nanodrug delivery systems
- Author
-
Yingze Wang, Xinhe Xiong, Xing-Jie Liang, Yan Wen, Wei Zhang, Zhongxiao Han, and Xiao-Li Liu
- Subjects
Drug ,Cancer Research ,Colorectal cancer ,media_common.quotation_subject ,Review ,02 engineering and technology ,lcsh:RC254-282 ,Camptothecins ,03 medical and health sciences ,0302 clinical medicine ,medicine ,drug delivery system ,media_common ,biology ,business.industry ,Topoisomerase ,Cancer ,021001 nanoscience & nanotechnology ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,nanomedicine ,Oncology ,Drug development ,030220 oncology & carcinogenesis ,Drug delivery ,biology.protein ,Cancer research ,cancer therapy ,0210 nano-technology ,Liver cancer ,business ,Camptothecin ,medicine.drug - Abstract
The drug camptothecin has a wide range of antitumor effects in cancers including gastric cancer, rectal and colon cancer, liver cancer, and lung cancer. Camptothecin-based drugs inhibit topoisomerase 1 (Topo 1), leading to destruction of DNA, and are currently being used as important chemotherapeutic agents in clinical antitumor treatment. However, the main obstacle associated with cancer therapy is represented by systemic toxicity of conventional anticancer drugs and their low accumulation at the tumor site. In addition, low bioavailability, poor water solubility, and other shortcomings hinder their anticancer activity. Different from traditional pharmaceutical preparations, nanotechnology-dependent nanopharmaceutical preparations have become one of the main strategies for different countries worldwide to overcome drug development problems. In this review, we summarized the current hotspots and discussed a variety of camptothecin-based nanodrugs for cancer therapy. We hope that through this review, more efficient drug delivery systems could be designed with potential applications in clinical cancer therapy.
- Published
- 2017
5. Co-Delivery of Itraconazole and Docetaxel by Core/Shell Lipid Nanocells for Systemic Antiangiogenesis and Tumor Growth Inhibition
- Author
-
Lu Liu, Xing-Jie Liang, Chukwunweike Ikechukwu Okeke, Ahmed Shaker Eltahan, Jing Chen, Weisheng Guo, Mengqi Xu, An-Qi Yang, Yingze Wang, and Tingbin Zhang
- Subjects
Drug ,Angiogenesis ,media_common.quotation_subject ,Biomedical Engineering ,Pharmaceutical Science ,Medicine (miscellaneous) ,Bioengineering ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,chemistry.chemical_compound ,Antiangiogenesis Therapy ,medicine ,General Materials Science ,media_common ,Tumor microenvironment ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,PLGA ,chemistry ,Docetaxel ,Drug delivery ,Cancer research ,Systemic administration ,0210 nano-technology ,medicine.drug - Abstract
The combination of antiangiogenesis with chemotherapy has become a promising multi-modal combinational therapy for solid tumor. However, hypoxia-mediated resistance and the subsequent treatment failure associated with antiangiogenesis therapy have limited the maximization of this promising approach. It remains a major challenge to balance the effect of angiogenesis and the accumulation of the cytotoxic drug within the tumor microenvironment. In this study, we report a nanotechnology based drug delivery solution that would improve both the antiangiogenic activity and cytotoxic efficacy of the loaded drugs. We designed core-shell 'lipid nanocells' drug delivery systems (denoted as DTX/ITZ-LNCs), which entrapped the antiangiogenic drug itraconazole (ITZ) in the outside liposomal shell and encapsulated anticancer drug docetaxel (DTX) in the inner hydrophobic PLGA core. In vitro evaluations showed that the dual drug loaded DTX/ITZ-LNCs retained the cytotoxic efficacy of the DTX against both the sensitive and multidrug resistant breast cancer cell line MCF-7. DTX/ITZ-LNCs also effectively inhibited the vascular endothelial growth factor (VEGF) induced migratory and invasive actions of HUVECs and neovascularization of subcutaneously implanted matrigel plugs. The tumor growth of MCF-7 tumor xenograft model was effectively inhibited by the systemic administration of the DTX/ITZ-LNCs. Taken together, these results showed that the DTX/ITZ-LNCs provided a drug delivery platform that can optimize the combinatory effects of the antiangiogenic agent with a conventional chemotherapeutic agent.
- Published
- 2019
6. SRSF7 knockdown promotes apoptosis of colon and lung cancer cells
- Author
-
Yingze Wang and Yu Fu
- Subjects
0301 basic medicine ,A549 cell ,Cancer Research ,Gene knockdown ,Small interfering RNA ,Oncogene ,cell apoptosis ,Chemistry ,Cancer ,Articles ,medicine.disease ,03 medical and health sciences ,lung cancer ,splicing ,030104 developmental biology ,SR protein ,Oncology ,colon cancer ,Apoptosis ,serine/arginine-rich splicing factor 7 ,medicine ,Cancer research ,Lung cancer - Abstract
Serine/arginine-rich (SR) proteins are a family of important splicing factors, which are involved in multiple aspects of RNA processing, including splicing, mRNA nuclear export, mRNA stability and translation. Previous studies have identified a number of SR proteins that exhibit abnormal expression in various tumor types. In the present study, the expression and function of serine/arginine-rich splicing factor 7 (SRSF7) were investigated in colon and lung cancer. Using tissue immunohistochemistry, it was observed that SRSF7 was overexpressed in colon and lung cancer tissues. As the role of SRSF7 in cancer remains to be fully elucidated, the expression of SRSF7 was knocked down in the present study by transfecting SRSF7-specific small interfering RNAs (siRNAs) into the HCT116 colon cancer cell line and A549 lung cancer cell line, which exhibited elevated expression of SRSF7. MTS assays, western blot analysis, flow cytometry and spectrofluorometer analyses were performed to assess the effects of SRSF7 knockdown on the proliferation and apoptosis of cells. The results demonstrated that the expression of SRSF7 was efficiently knocked down by SRSF7 siRNA, and that SRSF7 knockdown inhibited proliferation and enhanced apoptosis of HCT116 and A549 cells. Further experiments involving BEAS-2B cells stably overexpressing SRSF7, and A549 cells with stable knockdown of SRSF7 revealed that SRSF7 regulated the splicing of the apoptosis regulator Fas. Collectively, these data indicated that SRSF7 is critical for the survival of colon and lung cancer cells, and may be a potential therapeutic target for the treatment of colon and lung cancer.
- Published
- 2017
7. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis
- Author
-
Baoyun Sun, Juan Lu, Xueyun Gao, Jun-Jie Yin, Yuliang Zhao, Yan Wu, Yingze Wang, Lee Jia, Jie Meng, Ding-Wu Shen, Michael M. Gottesman, Genmei Xing, Chunying Chen, Haiyong He, Xing-Jie Liang, Huan Meng, and Paul C. Wang
- Subjects
Male ,Metal Nanoparticles ,Mice, Nude ,Antineoplastic Agents ,Pharmacology ,Biology ,Endocytosis ,Mice ,Drug Therapy ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Nanotechnology ,Neoplasm ,chemistry.chemical_classification ,Cisplatin ,Multidisciplinary ,Transferrin ,Biological Sciences ,medicine.disease ,Magnetic Resonance Imaging ,Multiple drug resistance ,Nanomedicine ,chemistry ,Drug Resistance, Neoplasm ,Cell culture ,Cancer cell ,Cancer research ,Intracellular ,medicine.drug - Abstract
Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of mediation of cellular responses by [Gd@C82(OH)22]nnanoparticles, that [Gd@C82(OH)22]nmay reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant human prostate cancer (CP-r) cells. Here we report that exposure of the CP-r PC-3-luc cells to cisplatin in the presence of nontoxic [Gd@C82(OH)22]nnot only decreased the number of surviving CP-r cells but also inhibited growth of the CP-r tumors in athymic nude mice as measured by both optical and MRI. Labeling the CP-r PC-3 cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CP-r PC-3-luc cells with [Gd@C82(OH)22]nenhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring the defective endocytosis of the CP-r cancer cells. The results suggest that [Gd@C82(OH)22]nnanoparticles overcome tumor resistance to cisplatin by increasing its intracellular accumulation through the mechanism of restoring defective endocytosis. The technology can be extended to other challenges related to multidrug resistance often found in cancer treatments.
- Published
- 2010
8. Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: in vivo treatment and in vitro analysis
- Author
-
Xing-Jie Liang, Lee Jia, Xueyun Gao, Yuliang Zhao, Jianmin Xing, Yingze Wang, Paul C. Wang, Juan Lu, and Jie Meng
- Subjects
Cell signaling ,Cell Survival ,Cell ,Breast Neoplasms ,Gadolinium ,Biology ,Epigenesis, Genetic ,Nanocapsules ,In vivo ,Cell Line, Tumor ,medicine ,Humans ,General Materials Science ,Viability assay ,Particle Size ,Cytotoxicity ,Molecular biology ,In vitro ,Nanostructures ,Nanomedicine ,Treatment Outcome ,medicine.anatomical_structure ,Mechanism of action ,Cancer research ,Fullerenes ,medicine.symptom ,Crystallization - Abstract
Multi-hydroxylated endohedral metallofullerenol [Gd@C(82)(OH)(22)](n) nanoparticles possess the general physico-chemical characteristics of most nanoparticles. They also exhibit uniquely low toxicity and antineoplastic efficacy. In the current study, the molecular mechanisms and epigenetic characteristics of the antineoplastic action of these nanoparticles are explored. Human breast cancer MCF-7 and human umbilical vein endothelial ECV304 cell lines were used. Cell viability assay, cell hierarchical cluster analysis by cDNA microarray, semi-quantitative reverse transcription-polymerase chain reaction and Western blot analysis were conducted to investigate the changes in molecular and cellular signaling pathways caused by [Gd@C(82)(OH)(22)](n). The results demonstrated the high antitumor activity and low cytotoxicity of [Gd@C(82)(OH)(22)](n) nanoparticles both in vivo and in vitro. Their possible anti-tumor mechanisms were also discussed. The present study may provide new insight into the mechanism of action of these nanoparticles.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.